Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)
18 Years
N/A
Both
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Trial Information
Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)
OBJECTIVES:
- To establish a DNA bank from donor and recipient (prior to transplant) peripheral blood
for SNP studies.
- To establish a tissue bank for gene expression studies using donor and recipient
(post-transplant) peripheral blood samples.
- To establish a tissue bank for proteomic studies using donor and recipient blood and
urine samples.
- To establish a tissue bank for various studies using biopsy specimens.
- To establish a tissue bank for flow cytometric studies using recipient
(post-transplant), and sample from stem cell product.
OUTLINE: Peripheral blood samples are collected from donors prior to stem cell mobilization
and from patients prior to starting preparative regimen. Samples are studied by single
nucleotide polymorphism (SNP) analysis, SNP array, proteomic analysis, gene expression, and
other immunological laboratory methods. Blood, urine, and tissue samples are preserved for
future studies. Extra skin biopsies and gastrointestinal biopsies are performed at diagnosis
of graft-vs-host disease and preserved in a tissue bank for flow cytometric studies.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Approved for allogeneic stem cell transplantation
- Sample of the stem cells from donor must meet 1 of the following criteria:
- Total peripheral blood stem cell dose > 5 X10^6 CD34+ cells/kg
- Marrow cell dose > 3 X 10^8 nucleated cells/kg
PATIENT CHARACTERISTICS:
- Platelet count > 50,000/mm³ (for patients undergoing endoscopic biopsies)
- INR < 1.5 (for patients undergoing endoscopic biopsies)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
DNA bank from donor and recipient (prior to transplant) peripheral blood for single nucleotide polymorphism studies
Outcome Time Frame:
Completion of transplant
Safety Issue:
No
Principal Investigator
Madan Jagasia, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
United States: Federal Government
Study ID:
VICC BMT 0664
NCT ID:
NCT00900406
Start Date:
January 2007
Completion Date:
March 2010
Related Keywords:
- Breast Cancer
- Chronic Myeloproliferative Disorders
- Gestational Trophoblastic Tumor
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
- Neuroblastoma
- Ovarian Cancer
- Testicular Germ Cell Tumor
- Breast Neoplasms
- Neoplasms
- Graft vs Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Plasmacytoma
- Myelodysplastic Syndromes
- Preleukemia
- Myeloproliferative Disorders
- Neuroblastoma
- Ovarian Neoplasms
- Trophoblastic Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Gestational Trophoblastic Neoplasms
- Myelodysplastic-Myeloproliferative Diseases
Name | Location |
|---|---|
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee 37232-6838 |
| Vanderbilt-Ingram Cancer Center - Cool Springs | Nashville, Tennessee 37064 |
| Vanderbilt-Ingram Cancer Center at Franklin | Nashville, Tennessee 37064 |
